Heron Therapeutics, Inc. (NASDAQ:HRTX) announced positive topline results from its Phase 2 study of the investigational agent HTX-011 in subjects undergoing abdominoplasty (Study …
Heron Therapeutics Inc (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, …
In a research report published Wednesday, Cantor analyst Chiara Russo reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX) with a price …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …
Heron Therapeutics Inc (NASDAQ:HRTX) announced that the U.S.
Heron Therapeutics Inc (NASDAQ:HRTX) has found Phase 2 success with its lead product candidates for the prevention of post-operative pain, HTX-011 and HTX-011B. …
Heron Therapeutics Inc (NASDAQ:HRTX), has entered into an agreement with Tang Capital Partners, LP whereby Tang Capital will lend the Company up to …
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical …
In a research report issued Thuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …